Enanta Pharma Q3 EPS $(1.86) Beats $(2.33) Estimate, Sales $18.89M Beat $18.06M Estimate
Portfolio Pulse from mahesh@benzinga.com
Enanta Pharma (NASDAQ:ENTA) reported Q3 losses of $(1.86) per share, beating the analyst consensus estimate of $(2.33) by 20.17%. This is a 21.57% decrease over losses from the same period last year. The company also reported quarterly sales of $18.89 million, beating the analyst consensus estimate of $18.06 million by 4.61%. This is a 3.01% decrease over sales from the same period last year.
August 07, 2023 | 8:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Enanta Pharma reported better than expected Q3 earnings and sales, despite a decrease compared to the same period last year.
Enanta Pharma's better than expected Q3 earnings and sales could lead to a positive market reaction, despite the year-on-year decrease. The beat on both fronts indicates the company is performing better than what the market had anticipated, which is typically well received by investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100